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 Abstract Short episodes of ischemia (ischemic preconditioning) protect
the heart against ventricular arrhythmias during zero-flow ischemia and
reperfusion. However, in clinics, many episodes of ischemia present a resid-
ual ﬂow (low-ﬂow ischemia). Here we examined whether ischemic precondi-
tioning protects against ventricular arrhythmias during and after a low-ﬂow
ischemia and, if so, by what mechanism(s).
Isolated rat hearts were subjected to 60 min of low-ﬂow ischemia (12%
residual coronary ﬂow) followed by 60 min of reperfusion. Ischemic precon-
ditioning was induced by two cycles of 5 min of zero-ﬂow ischemia followed
by 5 and 15 min of reperfusion, respectively. Arrhythmias were evaluated as
numbers of ventricular premature beats (VPBs) as well as incidences of ven-
tricular tachycardia (VT) and ventricular ﬁbrillation (VF) during low-ﬂow
ischemia and reperfusion. Ischemic preconditioning signiﬁcantly reduced the
number of VPBs and the incidence of VT and of VF during low-ﬂow ischemia.
This antiarrhythmic effect of preconditioning was abolished by HOE 140 
(100 nM), a bradykinin B2 receptor blocker. Similar to preconditioning,
exogenous bradykinin (10 nM) reduced the number of VPBs and the inci-
dence of VT and of VF during low-ﬂow ischemia. Furthermore, the antiar-
rhythmic effects of both ischemic preconditioning and bradykinin were abol-
ished by glibenclamide (1 µM), a non-speciﬁc blocker of ATP-sensitive K+
(KATP) channels. Finally, the antiarrhythmic effects of both ischemic precon-
ditioning and bradykinin were abolished by HMR 1098 (10 µM), a sarcolem-
mal KATP channel blocker but not by 5-hydroxydecanoate (100 µM), a mito-
chondrial KATP channel blocker. In conclusion, ischemic preconditioning
protects against ventricular arrhythmias induced by low-ﬂow ischemia, and
this protection involves activation of bradykinin B2 receptors and subsequent
opening of sarcolemmal but not of mitochondrial KATP channels.
 Key words Preconditioning – ischemia/reperfusion – bradykinin – KATP
channels – arrhythmias
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Introduction 
Brief episodes of ischemia and reperfusion (ischemic
preconditioning) protect the heart against a subsequent
ischemic injury [21]. Accordingly, ischemic precondi-
tioning confers protection against myocardial necrosis,
contractile dysfunction and ventricular arrhythmias
occurring during and/or after a subsequent ischemia [3,
20, 21, 29]. Most studies on preconditioning, however,
have focused on the protection against ischemia without
residual myocardial blood ﬂow (zero-ﬂow ischemia). Far
fewer studies have focused on the protection against
ischemia with a residual ﬂow (low-ﬂow ischemia). From
a clinical point of view, low-ﬂow ischemia is just as rele-
vant to study because ischemia can vary from mild to
severe and because life-threatening ventricular arrhyth-
mias occur not only during zero-ﬂow ischemia but also
during low-ﬂow ischemia [8]. Previous studies on low-
flow ischemia suggest that ischemic preconditioning
confers protection against myocardial necrosis [26] but
not against post-ischemic contractile dysfunction [4]. So
far, few studies [29, 30] have investigated the effect of
ischemic preconditioning on arrhythmias induced by
low-ﬂow ischemia and reperfusion. In these two studies
in dogs, low-ﬂow ischemia presumably occurred despite
complete coronary occlusion because of the collateral
circulation providing some residual myocardial blood
flow in the ischemic area in this species. The precise
degree of ischemia in these studies [29, 30], however, is
not known.
The aim of the present study was to determine
whether ischemic preconditioning protects against ven-
tricular arrhythmias induced by a perfusion-controlled
low-ﬂow ischemia and subsequent reperfusion and, if 
so, to elucidate the underlying mechanism(s). For this
purpose, we tested whether ischemic preconditioning
reduces the number of ventricular premature beats
(VPBs) and the incidence of ventricular tachycardia (VT)
and of ventricular fibrillation (VF) during low-flow
ischemia and reperfusion in isolated rat hearts.
Previous studies [23, 30] on antiarrhythmic effects of
preconditioning proposed a role for bradykinin and
bradykinin B2 receptors that have also been implicated in
antinecrotic effects of preconditioning [2, 27] and in car-
dioprotection in general [13]. In a recent report on limi-
tation of myocardial necrosis, B2 receptors were sug-
gested to be linked to the opening of mitochondrial
(mito) but not sarcolemmal (sarc) ATP-sensitive K+
(KATP) channels [15]. In addition, recent reports have
implicated mitoKATP channels as the end effectors in the
downstream signaling pathways of early and delayed
preconditioning against myocardial necrosis [11, 22]. 
In the signaling pathway of preconditioning against
arrhythmias, however, a relationship between B2 recep-
tors and sarcKATP and/or mitoKATP channels has not yet
been deﬁned.
Therefore, to elucidate underlying mechanism(s) of
potential antiarrhythmic effects of preconditioning dur-
ing low-ﬂow ischemia and reperfusion, we treated pre-
conditioned rat hearts with HOE 140 (100 nM), a selec-
tive blocker of B2 receptors. Additionally, we perfused the
hearts with exogenous bradykinin (10 nM) during low-
ﬂow ischemia to reproduce (endogenous) bradykinin-
mediated cardioprotection after preconditioning. To link
bradykinin to KATP channels, we tested whether gliben-
clamide (1 µM), a non-speciﬁc blocker of KATP channels
[14], abolishes the effects of both ischemic precondition-
ing and exogenous bradykinin. Finally, to identify the
KATP channel subtype mediating the antiarrhythmic
effects of preconditioning during low-ﬂow ischemia, we
treated preconditioned hearts as well as bradykinin-per-
fused heart with HMR 1098 (10 µM), a selective sarcKATP
channel blocker [6, 10], or with 5-hydroxydecanoate 
(5-HD; 100 µM), a selective mitoKATP channel blocker
[12, 18].
Methods 
 Isolated rat heart preparation
Treatment of animals conformed to the rules of the Swiss
Federal Act on Animal Protection (1998), and was
approved by the veterinary department of Basel (Switzer-
land). Male Sprague Dawley rats (RCC Ltd., Füllinsdorf,
Switzerland), weighing 300 – 350 g were anesthetized
using intraperitoneal injection of 30 mg/kg sodium pen-
tobarbital (Nembutal, Abbott Laboratories, Chicago, IL,
USA). After midline sternotomy, hearts were excised rap-
idly and perfused within 30 sec as previously described
[35]. All hearts were perfused at a constant pressure of 80
mm Hg with a ﬁltered (pore size 0.65 µm) nonrecirculat-
ing modiﬁed Krebs-Henseleit buffer containing (in mM)
NaCl 117.0, KCl 4.3, MgCl2 1.2, CaCl2 2.0, NaHCO3 25.0,
EDTA 0.5, glucose 15.0, and albumin 10.0 mg/L at pH 7.4.
This buffer was saturated with 95% O2/5% CO2 ensuring
a minimal pO2 of 550 mm Hg. During all experiments, the
hearts were immersed in perfusate maintained at exactly
37.0 °C [35] preventing bradycardia due to cardiac cool-
ing.
 Experimental protocols
The experimental protocols are presented in Fig. 1. Low-
ﬂow ischemia was induced for 60 min by reducing the
perfusion pressure from 80 to 15 mm Hg leading to a
reduction of coronary ﬂow of ≈90%. To prevent brady-
cardia and asystole during low-flow ischemia, hearts
were paced (as recommended by [5]) at 300 beats per min
via a pair of platinum pacemaker wires implanted in the
right ventricular free wall and connected to a pulse gen-
erator (Grass SD 5, Grass Instruments, Quincy, MA,
USA). Reperfusion was induced by normalizing the per-
fusion pressure to 80 mm Hg for 60 min. This protocol
did not cause any macroscopically visible myocardial
necrosis in our experiments as evaluated by 2,3,5 tri-
phenyltetrazolium chloride (TTC) staining [1] after 60 min
of low-flow ischemia and prolonged reperfusion (120
min) in additional experiments. Additionally, this pro-
tocol did not cause contractile dysfunction in control
hearts (Table 1).
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Hearts were randomly assigned to one of 14 groups:
(I) Control: hearts subjected to low-ﬂow ischemia and
reperfusion without drug treatment or ischemic precon-
ditioning (n = 10); (II) Preconditioning: hearts subjected
to ischemic preconditioning consisting of two cycles of 
5 min of global zero-ﬂow ischemia followed by 5 and 
15 min of reperfusion, respectively before low-flow
ischemia (n = 11); (III) HOE 140: hearts treated with HOE
140 (100 nM) 60 min before low-ﬂow ischemia until the
end of the experiment (n = 10); (IV) HOE 140 + Precon-
ditioning: hearts treated with HOE 140 (100 nM) 30 min
before the preconditioning ischemia until the end of the
experiment (n = 10); (V) Bradykinin: hearts treated with
bradykinin (10 nM) 15 min before low-flow ischemia
until the end of the experiment (n = 11); (VI) Gliben-
clamide + Preconditioning: hearts treated with gliben-
clamide (1 µM, a non-speciﬁc blocker of KATP channels
[14]) 30 min before the preconditioning ischemia until
the end of the experiment (n = 10); (VII) Glibenclamide
+ Bradykinin: hearts treated with glibenclamide (1 µM)
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Fig. 1 Experimental protocols. All
hearts were submitted to 60 min of
low-flow ischemia (12% residual
coronary flow) followed by 60 min of
reperfusion. Drug treatment is indi-
cated by brackets and timing of inter-
ventions is indicated at the bottom.
DMSO, dimethylsulfoxide; 5-HD, 5-
hydroxydecanoate
and bradykinin (10 nM) 60 and 15 min before low-ﬂow
ischemia, respectively, until the end of the experiment 
(n = 10); (VIII) DMSO + Preconditioning: hearts treated
with DMSO (0.01%, the vehicle of glibenclamide) 30 min
before the preconditioning ischemia until the end of the
experiment (n = 3); (IX) HMR 1098: hearts treated with
HMR 1098 (10 µM, a selective sarcKATP channel blocker
[6, 10] in a concentration known to block >90% of the
sarcolemmal KATP channel current [17]) 60 min before
low-ﬂow ischemia until the end of the experiment (n = 8);
(X) HMR 1098 + Preconditioning: hearts treated with
HMR 1098 (10 µM) 30 min before the preconditioning
ischemia until the end of the experiment (n =10); (XI)
HMR 1098 + Bradykinin: hearts treated with HMR 1098
(10 µM) and bradykinin (10 nM) 60 and 15 min before
low-flow ischemia, respectively, until the end of the
experiment (n = 9) ; (XII) 5-HD: hearts treated with 5-HD
(100 µM, a selective mitoKATP channel blocker [12, 18])
60 min before low-ﬂow ischemia  until the end of the
experiment (n = 9); (XIII) 5-HD + Preconditioning:
hearts treated with 5-HD (100 µM) 30 min before the
preconditioning ischemia until the end of the experiment
(n = 10); and (XIV) 5-HD + Bradykinin: hearts treated
with 5-HD (100 µM) and bradykinin (10 nM) 60 and 15
min before low-ﬂow ischemia, respectively, until the end
of the experiment (n = 12).
 Measurement of hemodynamic variables
Coronary ﬂow was measured within the aortic canula
using an inline ﬂowprobe (Transonic 2N) connected to a
transit time ﬂowmeter (Transonic TTFM-SA type 700,
Hugo Sachs Elektronik-Harvard Apparatus, March-Hug-
stetten, Germany). Left ventricular (LV) pressure was
measured by a ﬂuid-ﬁlled polyethylene catheter inserted
through the left atrial appendage into the LV cavity. The
catheter was connected to an Isotec pressure transducer
(Hugo Sachs Elektronik-Harvard Apparatus, March-
Hugstetten, Germany). LV developed pressure was
deﬁned as the difference between systolic and diastolic
values of LV pressure. Simultaneously, a bipolar elec-
trocardiogram (ECG) was recorded from electrodes
implanted superﬁcially in the right atrium and the apex.
A digitized readout of the LV pressure and the ECG was
recorded at 200 Hz sampling rate throughout the exper-
iment using PowerLab 8e (AD Instruments, Castle Hill,
Australia) connected to a Macintosh computer (Apple,
Cupertino, CA, USA) running Chart software (AD Instru-
ments, Castle Hill, Australia).
 Analysis of arrhythmias
Analysis of ventricular arrhythmias was based on the
Lambeth Conventions [32]. Accordingly, arrhythmias
were categorized as single ventricular premature beat
(VPB), ventricular tachycardia (VT, run of four or more
consecutive VPBs with corresponding effective LV pres-
sure) or ventricular ﬁbrillation (VF, ECG waves of irreg-
ular morphology without corresponding effective LV
pressure). Salvos (VPB doublet or triplet) were included
in the analysis of VPB and, therefore, not analyzed sepa-
rately. However, persistent bigeminies (alternating nor-
mal and premature beats) were not included in the analy-
sis as they occurred in only three hearts. Sustained and
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Table 1 Hemodynamic results
Coronary flow (ml/min) Left ventricular developed pressure (mm Hg)
n Before Low-flow End Before Low-flow End
(hearts) Baseline ischemia Ischemia Reperfusion Baseline ischemia Ischemia Reperfusion
Control 10 22.6  6.0 19.1  5.6 2.5  1.2 14.7  7.0 79  5 79  5 11  5 70  16
Preconditioning 11 24.0  6.7 23.0  6.2 3.0  0.7 14.0  4.2 81  8 79  12 13  5 72  10
HOE 140 10 23.2  3.7 20.0  4.5 3.0  1.0 15.5  4.3 79  3 79  4 13  4 74  5
HOE 140 + Preconditiong 10 23.8  2.6 21.7  3.2 2.8  0.8 16.4  5.8 78  4 77  4 12  3 70  6
Bradykinin 11 24.1  5.2 24.1  3.4* 3.1  0.5 18.9  5.8 76  5 77  4 13  2 70  9
Glibenclamide + Preconditioning 10 25.4  2.6 16.9  1.8 2.7  0.7 10.0  2.2 78  7 72  8 11  3 66  9
Glibenclamide + Bradykinin 10 25.2  3.7 19.7  5.9 2.4  0.9 11.2  4.8 82  6 80  9 10  2 66  14
HMR 1098 8 23.1  5.1 20.0  3.6 2.4  0.7 14.5  5.0 82  6 81  4 14  4 78  23
HMR 1098 + Preconditioning 10 23.2  3.5 15.7  2.1 3.2  0.8 10.0  1.4 76  5 72  11 9  2 62  8
HMR 1098 + Bradykinin 9 24.8  5.4 20.0  4.0 2.7  0.6 16.8  4.1 81  8 80  6 12  4 72  10
5-HD 9 23.5  4.2 21.3  3.6 2.2  0.7 15.1  3.4 80  5 81  4 12  3 63  12
5-HD + Preconditioning 10 22.9  2.7 21.9  3.0 2.9  0.4 14.2  3.2 79  2 80  2 11  3 70  4
5-HD + Bradykinin 12 23.2  5.8 23.8  5.8 2.7  0.7 15.7  3.5 80  6 79  6 13  3 72  11
Values are mean  SD. Low-flow ischemia values are averaged over the entire 60-min period. Note that at baseline, during, and after low-flow ischemia, neither coronary
flow nor left ventricular (LV) developed pressure significantly differed among groups. *P < 0.05 vs. control
spontaneously reverted VF were not analyzed separately,
and VF persisting longer than 30 sec was terminated by
a bolus of 0.25 mg lidocaine hydrochloride (Sintetica,
Mendrisio, Switzerland) injected into the perfusion can-
ula proximal to the aorta [36]. After 5-min washout, the
contractile and electrophysiological properties were
restored [36] and the experiment was continued to avoid
censoring of the data as recommended by the Lambeth
Conventions [32].
 Chemicals
HOE 140 and HMR 1098 were gifts from Aventis (Frank-
furt, Germany). Bradykinin, glibenclamide (= gly-
buride), and 5-HD were purchased from Sigma Chemi-
cal Co. (St. Louis, MO, USA). Glibenclamide was dis-
solved in dimethylsulfoxide (DMSO) before it was added
to the perfusate, and the ﬁnal concentration of DMSO
was 0.01%.
 Evaluation and statistical analysis
Coronary flow and LV developed pressure were
expressed as mean ± SD. The number of VPBs was eval-
uated on the digitized ECG at 5-min intervals. Because of
non-Gaussian distribution, the number of VPBs was
expressed as median with interquartile range that is the
distance between 25th and 75th percentile [34]. Finally, the
incidence of VT and VF during low-ﬂow ischemia and
reperfusion was evaluated on the digitized ECG and pres-
sure readouts. This analysis was to represent the pres-
ence or absence or ventricular tachyarrhythmias (disre-
garding the number and duration of VT or VF episodes).
Statistical comparisons of coronary flow and LV
developed pressure among groups were performed by
one-way analysis of variance (ANOVA) followed by
Dunett’s test to detect groups different from control.
Comparisons of the incidence of VT and of VF among
groups were performed by chi-squared analysis followed
by Fisher’s Exact test. Differences were considered sig-
nificant for p values <0.05. For comparison of VPBs
among groups, the number of VPBs were pooled during
low-flow ischemia and during reperfusion for each
experiment and analyzed by the Kruskal Wallis test fol-
lowed by multiple Mann-Whitney U test with downward
adjustment of the a level for 14 groups (0.004). Early
reperfusion VPBs were analyzed separately during the
ﬁrst 5 min of reperfusion using Kruskal Wallis test fol-
lowed by Mann-Whitney U test with downward adjust-
ment. Statistical computations were done using Prism
software (GraphPad, San Diego, CA, USA; version 3.0a)
and Statview (SAS Institute, Cary, NC, USA; version 5.0).
The sample size of the various groups was chosen to sta-
tistically detect a difference in the incidence of VF of at
least 50% [34].
Results
 Exclusions
We used a total of 141 isolated rat hearts for this study.
Of these, eight hearts were excluded due to unstable LV
pressure readings during stabilization.
 Hemodynamic variables
At baseline, no signiﬁcant differences of coronary ﬂow
and LV developed pressure could be detected among the
groups (Table 1; p = 0.95 and 0.31, respectively). How-
ever, after bradykinin treatment, coronary flow was
slightly, but signiﬁcantly, higher than in control hearts.
Additionally, glibenclamide and HMR 1098 caused a
slight decrease in coronary ﬂow that was not signiﬁcantly
different from control. Nevertheless, LV developed pres-
sure was similar after drug treatment and before low-ﬂow
ischemia (p > 0.26). Inducing low-flow ischemia by
reducing the perfusion pressure led to a reduction of
coronary ﬂow and LV developed pressure from 23.9 ± 4.4
to 2.8 ± 0.7 mL/min (= 11.8% residual coronary ﬂow) and
from 79.1 ± 5.1 to 11.6 ± 3.3 mm Hg, respectively (Table
1). Throughout this low-ﬂow ischemia, coronary ﬂow
and LV developed pressure values were not signiﬁcantly
different among the groups (p = 0.14 and 0.16, respec-
tively). During reperfusion, coronary ﬂow was similar in
all groups except in the ﬁrst 15 min of reperfusion where
flow was reduced in glibenclamide- and HMR 1098-
treated hearts. In the other groups, coronary flow
returned to near baseline levels in the ﬁrst 5 min of reper-
fusion and subsequently fell slightly to ≈60% of baseline
levels. At the end of reperfusion, however, no group sig-
nificantly differed from control hearts. Similarly, LV
developed pressure did not differ among the groups at
the end of reperfusion (p = 0.13). Finally, coronary ﬂow
and LV developed pressure in preconditioned hearts
receiving DMSO (the vehicle of glibenclamide) were not
different from preconditioned hearts without DMSO
throughout the experiments, excluding potential hemo-
dynamic effects of DMSO.
 Ventricular premature beats
At baseline, the number of VPBs was similarly low in all
groups (Fig. 2A and 2B, p = 0.99). During low-flow
ischemia, ischemic preconditioning significantly
reduced the number of VPBs. Speciﬁcally, the median
number of VPBs was significantly lower in precondi-
tioned hearts than in control hearts during low-flow
ischemia (Fig. 2A). This protection was abolished when
hearts were pretreated with HOE 140. However, the
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Fig. 2 A Number of ventricular prema-
ture beats of groups I to VII during 60
min of low-flow ischemia and 60 min of
reperfusion. Values are medians with
quartiles (25th and 75th percentile) eval-
uated at 5-min intervals for 10 – 11 rat
hearts per group. *P < 0.05 vs. control.
B Number of ventricular premature
beats of the groups IX to XIV receiving
HMR 1098 or 5-HD, the selective sar-
colemmal and mitochondrial K+ATP
channel blockers, respectively during
60 min of low-flow ischemia and 60 min
of reperfusion. Values are medians with
quartiles (25th and 75th percentile) eval-
uated at 5-min intervals for 8-12 rat
hearts per group. *P < 0.05 vs. control
(shown on Fig. 2A)
A
B
number of VPBs in HOE 140-treated hearts was not
higher than in control hearts (p = 0.17). Similar to pre-
conditioning, the number of VPBs in bradykinin-treated
hearts was significantly reduced during low-flow
ischemia. The protective effects of both preconditioning
and exogenous bradykinin were abolished by gliben-
clamide increasing the number of VPBs beyond that of
control hearts. Similarly, the protective effect of both pre-
conditioning and bradykinin was abolished by HMR
1098, and was not modiﬁed by 5-HD (Fig. 2B). However,
in hearts treated with HMR 1098 or 5-HD alone (without
preconditioning or bradykinin), the number of VPBs was
not different from control during low-flow ischemia 
(p = 0.47).
During reperfusion, far fewer VPBs occurred than
during low-ﬂow ischemia in all groups (Fig. 2A and 2B).
In addition, the median number of VPBs was similar in
all groups except in glibenclamide-treated hearts where
the median number of VPBs was signiﬁcantly higher than
in control hearts. This difference was particularly pro-
nounced during the ﬁrst 5 min of reperfusion. Finally, the
number of VPBs in preconditioned hearts receiving
DMSO was not different from preconditioned hearts
without DMSO throughout the experiments (p = 0.25;
data not shown), excluding potential electrophysiologic
effects of DMSO.
 Incidence of VT and VF
During low-ﬂow ischemia, similar ﬁndings as for VPBs
were observed for the incidence of VT and VF (Fig. 3).
Accordingly, ischemic preconditioning significantly
reduced the incidence of both VT and VF from 80% in
control to 27%. This protection, however, was signiﬁ-
cantly attenuated by HOE 140 since HOE 140 given
before preconditioning increased the incidence of VT
and VF to 70%. Nevertheless, treatment with HOE 140
alone (without preconditioning) did not affect the inci-
dence of VT and VF. Similar to preconditioning, brady-
kinin treatment signiﬁcantly reduced the incidence of
both VT and VF during low-ﬂow ischemia to 27% and
18%. As for the number of VPBs, glibenclamide abol-
ished the protective effects of both preconditioning and
bradykinin, increasing the incidence of VT and VF dur-
ing low-ﬂow ischemia similar to that of control hearts.
Similarly, treatment with HMR 1098 abolished the pro-
tective effect of both preconditioning and bradykinin
increasing the incidence of both VT and VF during low-
ﬂow ischemia to 90%. In contrast, treatment with 5-HD
did not alter the effect of both preconditioning and
bradykinin on the incidence of both VT and VF. How-
ever, in hearts treated with HMR 1098 or 5-HD alone
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Fig. 3 Incidence of ventricular tachy-
cardia (VT) and of ventricular fibrillation
(VF) during 60 min of low-flow ischemia
and during 60 min of reperfusion repre-
senting the presence or absence or ven-
tricular tachyarrhythmias in a particular
heart (independent on number and
duration of VT and of VF). *P < 0.05 vs.
control
(without preconditioning or bradykinin), the incidence
of VT and VF was not different from control.
During reperfusion, the incidence of VT and VF was
lower than during low-ﬂow ischemia. However, gliben-
clamide signiﬁcantly increased the incidence of VT dur-
ing reperfusion. Nevertheless, the incidence of VF in all
groups was not significantly different from control
hearts. Finally, the incidence of VT and VF in precondi-
tioned hearts receiving DMSO was not different from
preconditioned hearts without DMSO during low-ﬂow
ischemia and reperfusion (p > 0.51; data not shown).
Discussion
In this study in isolated rat hearts, we demonstrate that
ischemic preconditioning protects against ventricular
arrhythmias induced by a low-ﬂow ischemia and that
this protection involves activation of bradykinin B2
receptors and subsequent opening of sarcKATP but not of
mitoKATP channels. Evidence for an antiarrhythmic effect
of ischemic preconditioning during low-ﬂow ischemia 
is that two cycles of 5 min of global zero-ﬂow ischemia
signiﬁcantly reduced both the number of VPBs and the
incidence of VT and of VF during a 60-min low-flow
ischemia at a deﬁned residual coronary ﬂow of 12%. Fur-
thermore, evidence that bradykinin B2 receptors are
involved in this protection is that the B2 blocker HOE 140
abolished the effect of preconditioning and that exoge-
nous bradykinin reproduced the antiarrhythmic effects
of preconditioning during low-ﬂow ischemia. Moreover,
evidence for bradykinin B2 receptor-linked opening of
KATP channels arises from the ﬁnding that glibenclamide
abolished the antiarrhythmic effects of both precondi-
tioning and exogenous bradykinin in our experiments.
Finally, evidence for a role of sarcKATP rather than
mitoKATP channels in this form of protection is that HMR
1098, but not 5-HD, abolished the protective effects of
both preconditioning and exogenous bradykinin against
arrhythmias during low-ﬂow ischemia. Exclusive admin-
istration of either selective KATP channel blocker (without
preconditioning or bradykinin) did not affect the num-
ber of VPBs or the incidence of VT and of VF during 
low-ﬂow ischemia or reperfusion. This excludes poten-
tial proarrhythmic effects of HMR 1098 or 5-HD that
would have undermined our conclusion. During reper-
fusion, too few arrhythmias occurred in control hearts
for any antiarrhythmic effect of preconditioning to be
detectable.
As described previously [29, 30], the antiarrhythmic
effects of ischemic preconditioning were not dependent
on the degree of ischemia in our experiments and pre-
conditioning can, thus, protect against subsequent
ischemic episodes when myocardial blood ﬂow is not
completely interrupted. Similar to our ﬁndings in low-
ﬂow ischemia, bradykinin has been suggested to under-
lie antiarrhythmic effects of preconditioning during
zero-ﬂow ischemia [30]. As in our experiments, HOE 140
abolished the antiarrhythmic effects of preconditioning
in these studies. Additionally, antiarrhythmic effects of
exogenous bradykinin have been reported in a previous
study in dogs [31]. Furthermore, a recent report showed
a link between bradykinin B2 receptor activation and
KATP channel opening in the effect of preconditioning
against myocardial necrosis [15]. Additionally, reperfu-
sion-induced arrhythmias after brief regional zero-ﬂow
ischemia have been shown to be suppressed after pre-
conditioning via KATP channel opening [16]. The present
study extends these studies by showing for the ﬁrst time
that antiarrhythmic effects of ischemic preconditioning
can be mediated by bradykinin B2 receptor activation
linked to sarcKATP channel opening.
Surprisingly, glibenclamide not only abolished pre-
conditioning and bradykinin-induced protection against
arrhythmias, but it signiﬁcantly increased the number of
VPBs beyond that of control hearts. However, gliben-
clamide did not increase the incidence of VT and of VF
beyond that of control hearts during low-ﬂow ischemia
(as a limitation of our study, such an increase would have
been impossible to detect with statistical significance
because of the high incidence of VT and of VF in control
hearts during low-ﬂow ischemia). Still, because of the
effects of glibenclamide on VPBs and on VT during
reperfusion, this drug may be favoring VPBs without
providing a substrate to maintain re-entrant tachy-
arrhythmias. KATP channels blockade by glibenclamide
can prolong action potential duration [9] and may give
rise to early and delayed afterdepolarizations, triggered
activity and, thus, VPBs [7]. Alternatively, it may be that
blocking solely KATP channels does not sufﬁciently alter
the dispersion of repolarization to cause re-entrant exci-
tations and, thus, to induce and maintain VT or VF.
The signal transduction of bradykinin B2 receptors to
KATP channel opening in preconditioned hearts remains
speculative. Bradykinin released from endothelial cells
during preconditioning can stimulate endothelial release
of nitric oxide and prostanoids, which have been shown
to activate the mitoKATP channel in rabbit ventricular
myocytes [2, 24]. However, B2 receptors are also present
on rat cardiomyocyte [19] where they lead to protein
kinase C (PKC) activation. Of interest, PKC potentiated
the opening of the mitoKATP channel in rabbit ventricu-
lar myocytes [25] and in isolated rat hearts [33]. Addi-
tionally, PKC phosphorylated the pore forming subunit
Kir6.2 [28] that has been proposed to be the sole pore
forming subunit of the sarcKATP channel in rabbit
ventricular myocytes [28]. Alternatively, bradykinin-
induced prostanoid release may account for sarcolem-
mal KATP channel activation [2]. Taken together, these
studies suggest a role for both mitoKATP and sarcKATP
channels in the cardioprotection afforded by precondi-
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© Steinkopff Verlag 2004
tioning. However, recent reports have implicated the
mitoKATP rather than the sarcKATP channels in the early
and delayed antinecrotic effect of preconditioning [11,
22]. By contrast, our results showed that the sarcKATP, but
not the mitoKATP, channels mediate the antiarrhythmic
effects of preconditioning during low-flow ischemia.
Possible mechanisms responsible for this antiarrhyth-
mic effect of sarcKATP channel activation might include
shortening of the cardiac action potential duration and
membrane hyperpolarization, which would lead to a
reduction in Ca2+ overload and a preservation of ATP. 
During reperfusion, too few arrhythmias occurred in
control hearts for any antiarrhythmic effect of precondi-
tioning to be detectable. However, in glibenclamide-
treated hearts, the number of VPBs and the incidence of
VT were higher than in control hearts. This indicates a
pro-arrhythmic effect of glibenclamide during reper-
fusion after a low-flow ischemia. Nevertheless, for
unknown reasons, the incidence of VF was not altered in
glibenclamide-treated hearts during reperfusion. As dis-
cussed above, it may be speculated that this drug can
cause runs of VPBs (thus leading to non-sustained VT, as
observed in our experiments), but does not provide a
substrate for sustained VT or VF during reperfusion.
During low-ﬂow ischemia, the residual coronary ﬂow
was 12% of baseline coronary ﬂow in our experiments.
This ﬂow is comparable to a previous study on precon-
ditioning against contractile dysfunction [4]. In that
study [4], however, low-ﬂow ischemia lasted longer (90
min) than in our experiments (60 min). In our experi-
ments, severe ischemia was absent as functional recovery
was complete after reperfusion and as myocardial necro-
sis (potentially confounding the analysis of arrhythmias)
was excluded by TTC staining. Finally, pretreatment
periods and concentrations of HOE 140, bradykinin,
glibenclamide, HMR 1098, and 5-HD were based on the
literature to ensure efﬁcacy of the drugs and not to dis-
tinguish trigger and mediator mechanisms of precondi-
tioning.
In conclusion, ischemic preconditioning protects
against ventricular arrhythmias induced by low-flow
ischemia in isolated rat hearts and this protection
involves activation of bradykinin B2 receptors and sub-
sequent opening of sarcKATP, but not of mitoKATP, chan-
nels. These ﬁndings support the view that antiarrhythmic
effects of ischemic preconditioning are brought about by
different mechanisms than antinecrotic effects.
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